Oct 28, 2021 / 12:00PM GMT
Operator
Good morning, everyone, and welcome to the Rafael Holdings conference call. Today's call is being recorded.
At this time, I would like to turn the call over to Barbara Ryan, Rafael Holdings' Investor Relations. Please begin.
Barbara Ryan - Rafael Holdings, Inc. - IR
Thank you, Lawrence. Welcome, and thank you all for joining us this morning. The purpose of today's call is to provide you with an update on the two Phase 3 clinical trials for devimistat, or CPI-613, AVENGER 500 for the treatment of patients with metastatic pancreatic cancer, and ARMADA 2000 for the treatment of patients with relapsed or refractory acute myeloid leukemia. Joining me this morning is Ameet Mallik, our Chief Executive Officer of Rafael Holdings.
Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of
Rafael Holdings Inc Phase 3 Trials of CPI-613 Clinical Data Update Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot